Details

Autor(en) / Beteiligte

• Davey, Jr, Richard T
• Dodd, Lori
• Proschan, Michael A
• Neaton, James
• Neuhaus Nordwall, Jacquie
• Koopmeiners, Joseph S
• Beigel, John
• Tierney, John
• Lane, H Clifford
• Fauci, Anthony S
• Massaquoi, Moses B F
• Sahr, Foday
• Malvy, Denis

Titel

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

Ist Teil von

• The New England journal of medicine, 2016-10, Vol.375 (15), p.1448-1456

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Ebola virus causes a devastating clinical illness that is associated with high mortality. In this trial conducted primarily in West Africa during an outbreak, ZMapp (a cocktail of three monoclonal antibodies against Ebola) showed some clinical activity. The 2014–2016 Ebola outbreak in West Africa was unprecedented in sheer scope, duration, and number of human casualties. 1 , 2 The outbreak resulted in more than 28,000 suspected or confirmed cases of Ebola virus disease (EVD) and more than 11,000 deaths. 3 Fragile health care infrastructures that were often already severely compromised by past years of civil strife played a substantial role in the propagation of the outbreak. Although the final postmortem analysis of the global response has yet to be written, there can be little doubt that the lack of therapeutic agents and vaccines with proven efficacy against EVD further contributed . . .